Navigation Links
BUSM study identifies new potential approaches to treat myelofibrosis
Date:6/23/2011

(Boston) A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting an enzyme that connects extracellular fibers. The study, published online in the Journal of Biological Chemistry, was conducted under the direction of Katya Ravid, PhD, professor of medicine and biochemistry and director of the Evans Center for Interdisciplinary Biomedical Research at BUSM.

Myelofibroisis, which currently affects between 16,000 and 18,500 Americans, occurs when bone marrow is replaced by scar tissue, resulting in a disruption in blood cell production.

Blood cells originate from precursor stem cells, which typically reside in the bone marrow. Red and white blood cells are categorized as cells with a myeloid lineage, which also includes megakaryocytic cells that give rise to blood-clotting platelets. An excess proliferation of myeloid cells causes a surplus production of fibers outside of the cell, which forms a dense matrix within the bone marrow that disrupts the formation of these blood cells.

Previous research has shown that the enzyme lysyl oxidase links and stabilizes the extracellular fibers, but as of yet, a treatment aimed at inhibiting the formation of these fibers has not been successful. Ravid's team demonstrated that inhibiting that enzyme using pharmacologic agents resulted in a significant decrease in the burden of myelofibrosis.

The team's investigation, which used a mouse model with a dense matrix, showed that while the megakaryotic cells that proliferate express high levels of lysyl oxidase, the normal, mature megakaryotic cells express scarce levels of the enzyme. The group also determined that lysyl oxidase boosts the proliferation of these cells, and also identified the mechanism that causes that to happen.

"This study uncovers a potential new approach aimed at cont
'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Long-term study shows effect of climate change on animal diversity
2. £2 million study to reveal workings of dementia genes
3. New study looks to define evangelicals and how they affect polling
4. CU-Boulder study suggests air quality regulations miss key pollutants
5. Researchers study acoustic communication in deep-sea fish
6. Study reveals homeowner perceptions in fire-prone areas
7. Researchers study how pistachios may improve heart health
8. Study: urban black bears live fast, die young
9. New study indicates link between weight gains during pregnancy and dieting history
10. Study reveals specific gene in adolescent men with delinquent peers
11. Sweat it out: UH study examines ability of sweat patches to monitor bone loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
(Date:3/18/2015)... March 18, 2015 As mobile payments ... revolutionary smart wallets and apps continue to be introduced into ... in the mobile payment industry in focus today are:  NXT-ID, ... (NYSE: BABA ), Apple Inc. (NASDAQ: ... Facebook Inc. (NASDAQ: FB ) NXT-ID, ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... world,s foremost scientific journals will publish results of a decades-long ... mountain rodents called marmots are growing larger, healthier and more ... study, published in Nature , is the first to ... and population size simultaneously in a species findings likely ...
... are reporting an in-depth validation of the discovery of ... The powdered material, made from natural clay, would be ... widely used to make plastics nanocomposites. A report on ... bi-weekly journal. Miriam Rafailovich and colleagues focused on ...
... to play an important role in type 2 diabetes and ... even broader role in disease, particularly in other metabolic disorders ... genes, the scientists may have identified future targets for drug ... British journal Diabetologia . "This protein could be ...
Cached Biology News:Climate change causes larger, more plentiful marmots, study shows 2Protein important in diabetes may also play a key role in heart disease, other disorders 2
(Date:4/16/2015)... Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) annual ... the Pennsylvania Convention Center, starting Saturday, April 18, in ... AACR holds claim to title of the oldest and ... journals, provides fellowships and grants, and partners with survivors ...
(Date:4/16/2015)... N.C. (PRWEB) April 16, 2015 ... Carolina at Charlotte (UNC Charlotte) spin-out company, announced ... L. Cooper, Ph.D., M.D., as Chief Operating Officer ... years of experience in developing clinical diagnostic and ... and infectious disease. , Cooper’s extensive career transcends ...
(Date:4/16/2015)... 2015  In recognition of World Hemophilia Day, Biogen ... to illuminate more than 15 prominent landmarks red throughout ... Zakim Bridge and Prudential Tower, Chicago,s ... Mercedes-Benz Superdome and Denver,s Coors ... April 17, and coincide with hemophilia community events in a ...
(Date:4/16/2015)... ROCKVILLE, Md. , April 16, 2015 /PRNewswire/ ... "RegeneRx") today announced its U.S. joint venture with ... conduct a phase 3 clinical trial for the ... dose-response, confirmatory trial for dry eye syndrome (DES) ... ReGenTree,s preservative-free eye drops, RGN-259/GBT201, this year.  Each ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... FRANCISCO, Feb. 19 Inverseon, Inc.,( http://www.inverseon.com ... of groundbreaking research led by Professor Richard ... Founder. In the March,article by Nguyen, et. ... Cell and,Molecular Biology 2008; 38: 256-262, entitled, ...
... continues to ... grow top strategic talent from within, WEST CONSHOHOCKEN, ... marketing agency serving the healthcare,industry, announced today several recent ... these senior executives, contributions and,commitment to the overall success ...
... Va., Feb. 19 Insmed Inc. (Nasdaq:,INSM), a ... it will host a conference call on Tuesday, ... results for the fourth quarter and full-year 2007.,Insmed ... results press,release before the market opens on March ...
Cached Biology Technology:Drug Reduces Airway Mucus in Preclinical Asthma Model 2Cadient Group Announces Recent Executive Promotions 2Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call 2
... Evaluated for its amino acid acceptor activity using ... Ala, Asp, Gly, Ile, Lys, Pro, Thr, Val, ... Unit Definition: One unit will yield an A ... water (1 cm light path). Physical ...
... use as a carrier in ... Physical form: Solution in 10 ... 1 mM EDTA Preparation Note: ... Concentration: 10 mg/mL ...
... Cleland’s Reagent, Immobilized ... FREEZE. Immobilized form of DTT on polyacrylamide resin ... (Cat. Nos. 233153 , 233156 , ... advantage that no soluble components are added to ...
... White crystalline solid. PACKAGED UNDER INERT ... Contaminants: DNases, proteases, RNases: none detected. ... ≤0.500; (100 mM, 1 cm, 280 nm): ... Soluble in H 2 O. RTECS EK1610000, ...
Biology Products: